Baird Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $68

Ultragenyx Pharmaceutical, Inc. +1.10%

Ultragenyx Pharmaceutical, Inc.

RARE

40.34

+1.10%

Baird analyst Joel Beatty maintains Ultragenyx Pharmaceutical (NASDAQ: RARE) with a Outperform and raises the price target from $57 to $68.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via